The Wallstreet journal reported on B+L being able to file an IPO last summer but that B+L was trying to bulk the company up with acquisitions prior to the sale. The acquisition was probably just another delay tactic by B+L management to delay showing the financials of the company in an IPO.
All the IPO talk for the last year and many excuses for not filing:
1. Have to buy ISTA and absorb the new acquired company first
2. Have to do a an unusual two month biding process first (with an unrealistic price that no one would pay)
3. Have to wait until the overall market conditions improve
4. Have to wait until the new CFO can be hired to work on the IPO. What was the last CFO and CEO doing for the last two years?
IPO. Don't hold your breath on this one. Since the company said that an IPO could have been filed last summer except for the (1-3) above, now that those conditions have been met an IPO from this company is due. If the IPO process is not started in the next few months look very carefully at the next excuse from the company for not filing. If the excuse does not look right then expect that there is something very wrong with the financials of this company. On the other hand, if an IPO is filed then there is a chance that B+L is truly a viable company and it maybe worth purchasing stock at the right price.
In the ophthalmic investment community most are tired of hearing about B+L and its potential. It is time for B+L to put up or shut up.